Covered recipient · General Payments record
JAMES M KRELL
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$142,969.98
225 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $122,192.75 | 43 |
| Travel and Lodging | $10,380.33 | 33 |
| Food and Beverage | $5,265.87 | 144 |
| Consulting Fee | $4,862.50 | 2 |
| Honoraria | $260.08 | 2 |
| Education | $8.45 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $35,599.87 | 54 |
| UCB, Inc. | $21,876.79 | 22 |
| Janssen Biotech, Inc. | $18,984.48 | 19 |
| Galderma Laboratories, L.P. | $17,591.95 | 22 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $16,806.58 | 12 |
| Lilly USA, LLC | $14,544.77 | 31 |
| Regeneron Healthcare Solutions, Inc. | $9,204.99 | 17 |
| Amgen Inc. | $5,104.60 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,563.12 | 5 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $208.20 | 14 |
| E.R. Squibb & Sons, L.L.C. | $154.17 | 8 |
| LEO Pharma Inc. | $94.76 | 5 |
| Arcutis Biotherapeutics, Inc. | $82.26 | 4 |
| Incyte Corporation | $53.62 | 3 |
| Novartis Pharmaceuticals Corporation | $46.95 | 2 |
| Dermavant Sciences, Inc. | $37.67 | 2 |
| Paratek Pharmaceuticals, Inc. | $15.20 | 1 |
Page 3 of 5; records 101–150 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAMES M KRELL
NPI 1932133659 · CMS profile ID 532194
Allopathic & Osteopathic Physicians / Dermatology
BIRMINGHAM, AL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 5; records 101–150 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1932133659?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAMES M KRELL, NPI 1932133659, CMS profile ID 532194. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932133659?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). JAMES M KRELL, NPI 1932133659, CMS profile ID 532194. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932133659?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- JAMES M KRELL, NPI 1932133659, CMS profile ID 532194, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1932133659?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
225 matching records · $142,969.98 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 225.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Dermavant Sciences, Inc. | $21.33 | 08/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127893170 | CMS |
| ABBVIE INC. | $3.56 | 08/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104109162 | CMS |
| Galderma Laboratories, L.P. | $5,400.00 | 08/02/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145310283 | CMS |
| Galderma Laboratories, L.P. | $85.85 | 08/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145310285 | CMS |
| E.R. Squibb & Sons, L.L.C. | $35.03 | 07/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101379234 | CMS |
| Galderma Laboratories, L.P. | $10.35 | 07/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145310273 | CMS |
| Galderma Laboratories, L.P. | $117.66 | 07/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145310275 | CMS |
| Galderma Laboratories, L.P. | $35.34 | 07/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145310277 | CMS |
| Galderma Laboratories, L.P. | $33.06 | 07/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145310279 | CMS |
| Galderma Laboratories, L.P. | $91.21 | 07/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145310281 | CMS |
| Galderma Laboratories, L.P. | $474.96 | 07/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145310265 | CMS |
| Galderma Laboratories, L.P. | $339.01 | 07/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145310267 | CMS |
| Galderma Laboratories, L.P. | $8.11 | 07/26/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145310269 | CMS |
| Galderma Laboratories, L.P. | $251.97 | 07/26/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145310271 | CMS |
| ABBVIE INC. | $96.15 | 07/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104109160 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.37 | 07/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101379224 | CMS |
| Lilly USA, LLC | $1,000.00 | 07/25/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135018222 | CMS |
| Regeneron Healthcare Solutions, Inc. | $38.29 | 07/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114092313 | CMS |
| Regeneron Healthcare Solutions, Inc. | $23.00 | 07/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114092315 | CMS |
| Regeneron Healthcare Solutions, Inc. | $23.71 | 07/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114092317 | CMS |
| Dermavant Sciences, Inc. | $16.34 | 07/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127893166 | CMS |
| Arcutis Biotherapeutics, Inc. | $19.05 | 07/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121051325 | CMS |
| ABBVIE INC. | $7.63 | 07/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104109158 | CMS |
| LEO Pharma Inc. | $21.45 | 07/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152638707 | CMS |
| ABBVIE INC. | $2,362.50 | 07/11/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103136455 | CMS |
| ABBVIE INC. | $32.79 | 07/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104109156 | CMS |
| Arcutis Biotherapeutics, Inc. | $24.84 | 07/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121051323 | CMS |
| ABBVIE INC. | $4.09 | 07/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104109154 | CMS |
| UCB, Inc. | $1,725.00 | 07/05/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143285045 | CMS |
| Janssen Biotech, Inc. | $127.24 | 07/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078254683 | CMS |
| Lilly USA, LLC | $1,000.00 | 07/02/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135036889 | CMS |
| ABBVIE INC. | $4,725.00 | 06/26/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103159272 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $8.77 | 06/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153810069 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,500.00 | 06/14/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118239008 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.74 | 06/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101379216 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.09 | 06/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101379220 | CMS |
| ABBVIE INC. | $11.75 | 06/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104109152 | CMS |
| Regeneron Healthcare Solutions, Inc. | $4,509.00 | 06/12/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114092311 | CMS |
| ABBVIE INC. | $113.07 | 06/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104109150 | CMS |
| ABBVIE INC. | $1,164.19 | 06/03/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104192406 | CMS |
| UCB, Inc. | $5.76 | 05/31/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143285032 | CMS |
| UCB, Inc. | $10.00 | 05/31/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143285037 | CMS |
| UCB, Inc. | $4,000.00 | 05/31/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143285041 | CMS |
| Amgen Inc. | $21.83 | 05/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117301751 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,113.39 | 05/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152155935 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $3,971.00 | 05/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152155943 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $124.26 | 05/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152155951 | CMS |
| ABBVIE INC. | $8.92 | 05/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104109148 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.93 | 05/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118239006 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $21.83 | 05/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153810087 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $349,889.97 | 127 |
| PY2024 | Recipient | $104.58 | 1 |
| PY2024 | Principal investigator | $536,588.94 | 222 |
| PY2023 | Recipient | $2,264.00 | 1 |
| PY2023 | Principal investigator | $334,687.62 | 118 |
| PY2022 | Recipient | $272.00 | 1 |
| PY2022 | Principal investigator | $222,449.12 | 76 |
| PY2021 | Principal investigator | $389,474.41 | 86 |
| PY2020 | Recipient | $1,922.60 | 2 |
| PY2020 | Principal investigator | $393,877.45 | 100 |
| PY2019 | Recipient | $3,192.59 | 3 |
| PY2019 | Principal investigator | $876,709.01 | 140 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
127 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,529.40 | 12/31/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata | No dispute reported | 06/30/2026 | 1202534143 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,550.00 | 12/24/2025 | Non-covered Recipient Entity Total Skin and Beauty Dermatology Center, PC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435278 |
| Principal investigator 1 | ABBVIE INC. | $1,862.42 | 12/22/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202531642 |
| Principal investigator 1 | ABBVIE INC. | $900.00 | 12/18/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202531152 |
| Principal investigator 1 | ABBVIE INC. | $282.60 | 12/18/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202531154 |
| Principal investigator 1 | ABBVIE INC. | $1,633.50 | 12/04/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202527070 |
| Principal investigator 1 | ABBVIE INC. | $6,110.40 | 12/04/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202527072 |
| Principal investigator 1 | Janssen Research & Development, LLC | $72.00 | 12/04/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175161838 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,689.10 | 12/01/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOL | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289019 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $900.00 | 11/13/2025 | Non-covered Recipient Entity Total Skin and Beauty Dermatology Center, PC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435263 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,390.00 | 11/13/2025 | Non-covered Recipient Entity Total Skin and Beauty Dermatology Center, PC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435269 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,227.42 | 11/13/2025 | Non-covered Recipient Entity Total Skin and Beauty Dermatology Center, PC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435275 |
| Principal investigator 1 | ABBVIE INC. | $969.00 | 11/06/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202523331 |
| Principal investigator 1 | ABBVIE INC. | $4,203.50 | 11/04/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202520531 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,185.40 | 10/23/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175161787 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,514.50 | 10/22/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOL | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287257 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 10/16/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202517151 |
| Principal investigator 1 | Janssen Research & Development, LLC | $144.00 | 10/16/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175162254 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $900.00 | 10/16/2025 | Non-covered Recipient Entity Total Skin and Beauty Dermatology Center, PC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435260 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8,955.00 | 10/10/2025 | Non-covered Recipient Entity Total Skin and Beauty Dermatology Center, PC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435256 |
| Principal investigator 1 | ABBVIE INC. | $1,380.70 | 10/09/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202514069 |
| Principal investigator 1 | ABBVIE INC. | $1,086.80 | 10/09/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202514071 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $618.80 | 10/08/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOL | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223286497 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $60.00 | 10/08/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOL | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286565 |
| Principal investigator 1 | ABBVIE INC. | $828.00 | 10/07/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202513407 |
| Principal investigator 1 | ABBVIE INC. | $809.40 | 10/02/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202513133 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $123.50 | 09/26/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223285943 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $415.00 | 09/26/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223285945 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,222.70 | 09/26/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285983 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9,000.00 | 09/11/2025 | Non-covered Recipient Entity Total Skin and Beauty Dermatology Center, PC | Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1252797096 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20.00 | 09/10/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223285261 |
| Principal investigator 1 | ABBVIE INC. | $1,128.60 | 09/04/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202509554 |
| Principal investigator 1 | ABBVIE INC. | $1,424.00 | 09/03/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202507974 |
| Principal investigator 1 | ABBVIE INC. | $6,185.90 | 09/03/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202507976 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,190.20 | 09/03/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285037 |
| Principal investigator 1 | Eli Lilly and Company | $27,901.00 | 08/25/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187891510 |
| Principal investigator 1 | ABBVIE INC. | $315.36 | 08/22/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202505611 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 08/22/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184229985 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,111.40 | 08/15/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284355 |
| Principal investigator 1 | ABBVIE INC. | $1,067.90 | 08/13/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202504399 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,501.50 | 08/08/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283979 |
| Principal investigator 1 | ABBVIE INC. | $1,470.90 | 08/05/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202501618 |
| Principal investigator 1 | ABBVIE INC. | $1,394.30 | 08/05/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202501620 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,154.90 | 08/01/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283615 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,185.40 | 07/31/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175162321 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,385.20 | 07/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283034 |
| Principal investigator 1 | Eli Lilly and Company | $3,457.35 | 07/17/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187891118 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,200.00 | 07/16/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175162066 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8,955.00 | 07/16/2025 | Non-covered Recipient Entity Total Skin and Beauty Dermatology Center, PC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435252 |
| Principal investigator 1 | ABBVIE INC. | $1,086.80 | 07/08/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497466 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 07/03/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175161755 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,858.00 | 07/03/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175162384 |
| Principal investigator 1 | ABBVIE INC. | $292.60 | 07/02/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202496585 |
| Principal investigator 1 | ABBVIE INC. | $1,352.10 | 07/02/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202496587 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $129.80 | 06/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210054 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $259.00 | 06/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210156 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $259.00 | 06/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210158 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $259.00 | 06/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210160 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $42.90 | 06/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210318 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $42.90 | 06/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210320 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $42.90 | 06/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210322 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.20 | 06/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210428 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $85.80 | 06/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210444 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $85.80 | 06/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210446 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $96.80 | 06/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210458 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $96.80 | 06/23/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210460 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,616.00 | 06/06/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280920 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,974.00 | 06/04/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175161735 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 06/04/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175161749 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 06/04/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175161830 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 06/04/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175161985 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 06/04/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162017 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 06/04/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162050 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 06/04/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162354 |
| Principal investigator 1 | ABBVIE INC. | $4,097.00 | 06/03/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202488761 |
| Principal investigator 1 | ABBVIE INC. | $1,131.40 | 06/03/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202488763 |
| Principal investigator 1 | ABBVIE INC. | $1,128.60 | 06/03/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202488765 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 05/21/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175161969 |
| Principal investigator 1 | Janssen Research & Development, LLC | $201.00 | 05/21/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162122 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,092.00 | 05/21/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162216 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,101.65 | 05/16/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279926 |
| Principal investigator 1 | ABBVIE INC. | $1,760.00 | 05/15/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202485165 |
| Principal investigator 1 | ABBVIE INC. | $1,880.00 | 05/15/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202485183 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,185.40 | 05/08/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175161825 |
| Principal investigator 1 | ABBVIE INC. | $4,106.20 | 05/07/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202483889 |
| Principal investigator 1 | ABBVIE INC. | $1,086.80 | 05/07/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202483891 |
| Principal investigator 1 | ABBVIE INC. | $1,380.70 | 05/07/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202483893 |
| Principal investigator 1 | ABBVIE INC. | $15,369.60 | 05/07/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202483895 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,310.00 | 04/28/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175161814 |
| Principal investigator 1 | Janssen Research & Development, LLC | $504.00 | 04/23/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175161947 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,746.00 | 04/18/2025 | Non-covered Recipient Entity Total Skin and Beauty Dermatology Center, PC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435248 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8,955.00 | 04/14/2025 | Non-covered Recipient Entity Total Skin and Beauty Dermatology Center, PC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435244 |
| Principal investigator 1 | Eli Lilly and Company | $1,500.00 | 04/11/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | No dispute reported | 06/30/2026 | 1187891122 |
| Principal investigator 1 | Janssen Research & Development, LLC | $332.00 | 04/07/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175162091 |
| Principal investigator 1 | ABBVIE INC. | $1,635.80 | 04/03/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202468797 |
| Principal investigator 1 | ABBVIE INC. | $1,232.40 | 04/03/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202469028 |
| Principal investigator 1 | ABBVIE INC. | $1,236.40 | 04/03/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202469032 |
| Principal investigator 1 | Eli Lilly and Company | $1,795.17 | 03/25/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187891120 |
| Principal investigator 1 | ABBVIE INC. | $9,609.70 | 03/07/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202459245 |
| Principal investigator 1 | ABBVIE INC. | $292.60 | 03/06/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202456464 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,190.20 | 03/05/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275987 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,042.00 | 03/03/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175161887 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,310.00 | 02/27/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175161878 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,466.00 | 02/27/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162391 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,763.60 | 02/26/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275585 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 02/20/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155088 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 02/20/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155100 |
| Principal investigator 1 | Eli Lilly and Company | $11,471.60 | 02/11/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187891438 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $12,324.38 | 02/07/2025 | Non-covered Recipient Entity Total Skin and Beauty Dermatology Center, PC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435239 |
| Principal investigator 1 | ABBVIE INC. | $5,056.00 | 02/06/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202446754 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,200.00 | 02/05/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184152057 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 02/05/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184152059 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,940.90 | 02/03/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274589 |
| Principal investigator 1 | Janssen Research & Development, LLC | $201.00 | 01/29/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175161992 |
| Principal investigator 1 | Janssen Research & Development, LLC | $201.00 | 01/29/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162073 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,228.00 | 01/27/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr PC | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162397 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 01/22/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202440483 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,342.65 | 01/22/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274323 |
| Principal investigator 1 | Janssen Research & Development, LLC | $581.97 | 01/21/2025 | Non-covered Recipient Entity Total Skin and Beauty Derm Ctr Admn | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175162303 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,355.10 | 01/21/2025 | Non-covered Recipient Entity Total Skin Beauty Dermatology Center Pc Total Dermatology | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226083336 |
| Principal investigator 1 | ABBVIE INC. | $400.00 | 01/20/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202440036 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $12,339.55 | 01/17/2025 | Non-covered Recipient Entity Total Skin And Beauty Dermatology Center PC | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | No dispute reported | 06/30/2026 | 1235992899 |
| Principal investigator 1 | Eli Lilly and Company | $26,456.00 | 01/07/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187893598 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $78.00 | 01/03/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273495 |
| Principal investigator 1 | ABBVIE INC. | $1,686.90 | 01/02/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202433422 |
| Principal investigator 1 | ABBVIE INC. | $1,390.40 | 01/02/2025 | Non-covered Recipient Entity TOTAL SKIN & BEAUTY DERMATOLOGY CEN | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202433426 |
| Principal investigator 1 | ABBVIE INC. | $218.60 | 01/02/2025 | Non-covered Recipient Entity TOTAL SKIN AND BEAUTY DERMATOLOGY CENTER PC | M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202435853 |